AU2012306810B2 - Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain - Google Patents

Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain Download PDF

Info

Publication number
AU2012306810B2
AU2012306810B2 AU2012306810A AU2012306810A AU2012306810B2 AU 2012306810 B2 AU2012306810 B2 AU 2012306810B2 AU 2012306810 A AU2012306810 A AU 2012306810A AU 2012306810 A AU2012306810 A AU 2012306810A AU 2012306810 B2 AU2012306810 B2 AU 2012306810B2
Authority
AU
Australia
Prior art keywords
seq
cometin
polypeptide
allodynia
hyperalgesia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012306810A
Other languages
English (en)
Other versions
AU2012306810A1 (en
Inventor
Teit E. Johansen
Jesper Roland Jorgensen
Lars Ulrik Wahlberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoba Therapeutics Aps
Original Assignee
Hoba Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoba Therapeutics Aps filed Critical Hoba Therapeutics Aps
Publication of AU2012306810A1 publication Critical patent/AU2012306810A1/en
Assigned to HOBA THERAPEUTICS APS reassignment HOBA THERAPEUTICS APS Request for Assignment Assignors: NSGENE A/S
Application granted granted Critical
Publication of AU2012306810B2 publication Critical patent/AU2012306810B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2012306810A 2011-09-05 2012-09-05 Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain Active AU2012306810B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531024P 2011-09-05 2011-09-05
US61/531,024 2011-09-05
PCT/DK2012/050330 WO2013034157A1 (en) 2011-09-05 2012-09-05 Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain

Publications (2)

Publication Number Publication Date
AU2012306810A1 AU2012306810A1 (en) 2014-03-13
AU2012306810B2 true AU2012306810B2 (en) 2017-09-28

Family

ID=46940179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012306810A Active AU2012306810B2 (en) 2011-09-05 2012-09-05 Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain

Country Status (8)

Country Link
US (2) US9474786B2 (enExample)
EP (1) EP2753347B1 (enExample)
JP (1) JP6145667B2 (enExample)
KR (1) KR102075881B1 (enExample)
CN (2) CN104105501B (enExample)
AU (1) AU2012306810B2 (enExample)
CA (1) CA2846511C (enExample)
WO (1) WO2013034157A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730710C (en) 2008-07-24 2021-06-08 Nsgene A/S Therapeutic use of a growth factor, metrnl
CA3086046C (en) * 2017-12-29 2023-02-21 Helixmith Co., Ltd. Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
CN110004223A (zh) * 2019-05-09 2019-07-12 苏州大学附属第一医院 一种用于预测早发型子痫前期发病的检测试剂盒
CA3217602A1 (en) * 2021-05-06 2022-11-10 Kenneth Petersen Prevention and treatment of chemotherapy-induced neuropathic pain
JP2024546758A (ja) * 2021-12-10 2024-12-26 ホバ セラピューティクス エーピーエス 侵害受容性疼痛の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009732A1 (en) * 2008-07-24 2010-01-28 Nsgene A/S Therapeutic use of a growth factor, metrnl

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
WO1993022437A1 (en) 1992-04-30 1993-11-11 N.V. Innogenetics S.A. New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
ES2326893T3 (es) 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
WO2001025427A1 (fr) 1999-10-01 2001-04-12 Kyowa Hakko Kogyo Co., Ltd. Adn reagissant a la contrainte de cisaillement
AU1395801A (en) 1999-11-30 2001-06-12 Innogenetics N.V. New uses of suppressive macrophage activation factors
WO2001055343A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2395676A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2403901A1 (en) 2000-05-02 2001-11-08 Human Genome Sciences, Inc. 29 human secreted proteins
NZ529126A (en) 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
AU2002364968A1 (en) 2001-12-21 2003-09-02 Diadexus, Inc. Compositions and methods relating to hepatic specific genes and proteins
WO2004035732A2 (en) 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050208500A1 (en) 2003-03-04 2005-09-22 Erlander Mark G Signatures of ER status in breast cancer
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
CN1982454A (zh) * 2005-12-15 2007-06-20 中国医学科学院北京协和医院 一种骨质疏松相关基因及其编码蛋白和用途
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009732A1 (en) * 2008-07-24 2010-01-28 Nsgene A/S Therapeutic use of a growth factor, metrnl

Also Published As

Publication number Publication date
CA2846511C (en) 2021-07-13
US20170143794A1 (en) 2017-05-25
EP2753347A1 (en) 2014-07-16
CN104105501B (zh) 2017-10-20
KR20140068148A (ko) 2014-06-05
HK1199395A1 (en) 2015-07-03
US9474786B2 (en) 2016-10-25
EP2753347B1 (en) 2016-08-03
JP6145667B2 (ja) 2017-06-14
CA2846511A1 (en) 2013-03-14
KR102075881B1 (ko) 2020-02-11
CN107596346A (zh) 2018-01-19
AU2012306810A1 (en) 2014-03-13
WO2013034157A1 (en) 2013-03-14
US20150231208A1 (en) 2015-08-20
CN104105501A (zh) 2014-10-15
US9861682B2 (en) 2018-01-09
JP2014529408A (ja) 2014-11-13

Similar Documents

Publication Publication Date Title
US7119066B2 (en) Modified ciliary neurotrophic factor (CNTF)
Gash et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys
Pittenger et al. Nerve growth factor and diabetic neuropathy
KR100271247B1 (ko) 청력손실 치료용 제약학적 조성물
US9861682B2 (en) Treatment of hyperalgesia, spontaneous pain, and phantom pain
CA2442159C (en) Treatment using neublastin polypeptides
KR101886029B1 (ko) 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
US20040077543A1 (en) Treatment using neublastin polypeptides
US6410510B1 (en) Administration modified ciliary neurotrophic factors
HK1199395B (en) Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
US20090136552A1 (en) Growth factors nsg28, nsg30, and nsg32
US6680291B1 (en) Modified ciliary neurotrophic factor, method of making and methods of use thereof
CA2379940A1 (en) Modified ciliary neurotrophic factor, method of making and methods of use thereof
CA3239550A1 (en) Treatment of nociceptive pain
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen
HK1186412B (en) Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HOBA THERAPEUTICS APS

Free format text: FORMER APPLICANT(S): NSGENE A/S

FGA Letters patent sealed or granted (standard patent)